Carna Biosciences Beheer

Beheer criteriumcontroles 2/4

De CEO Carna Biosciences is Kohichiro Yoshino, benoemd in Apr2003, heeft een ambtstermijn van 21.58 jaar. bezit rechtstreeks 1.75% van de aandelen van het bedrijf, ter waarde ¥ 103.51M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 12.8 jaar en 6.8 jaar.

Belangrijke informatie

Kohichiro Yoshino

Algemeen directeur

n/a

Totale compensatie

Percentage CEO-salaris	n/a
Dienstverband CEO	21.6yrs
Eigendom CEO	1.7%
Management gemiddelde ambtstermijn	12.8yrs
Gemiddelde ambtstermijn bestuur	6.8yrs

Recente managementupdates

Recent updates

Carna Biosciences, Inc. (TSE:4572) Shares May Have Slumped 26% But Getting In Cheap Is Still Unlikely

Aug 06

What Carna Biosciences, Inc.'s (TSE:4572) P/S Is Not Telling You

Apr 17

Health Check: How Prudently Does Carna Biosciences (TYO:4572) Use Debt?

Apr 11

How Much Did Carna Biosciences'(TYO:4572) Shareholders Earn From Share Price Movements Over The Last Five Years?

Feb 17

Health Check: How Prudently Does Carna Biosciences (TYO:4572) Use Debt?

Dec 26

CEO

Kohichiro Yoshino (75 yo)

21.6yrs

Tenure

Dr. Kohichiro Yoshino, Ph. D. is Independent Outside Director of Kringle Pharma, Inc since December 2018. Dr. Yoshino serves as the Chief Executive Officer of Carna Biosciences, Inc. He has been President...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Kohichiro Yoshino	CEO, President & Representative Director	21.6yrs	geen gegevens	1.75% ¥ 103.5m
Emi Yamamoto	GM of Business Mgt.	9.2yrs	geen gegevens	0.29% ¥ 16.9m
Masaaki Sawa	GM of Research & Development Division	no data	geen gegevens	0.56% ¥ 32.9m
Norio Aikawa	Head of Drug Discovery & Support Business	16.3yrs	geen gegevens	0.53% ¥ 31.6m
Akinori Arimura	GM of Clinical Development	5.8yrs	geen gegevens	0.086% ¥ 5.1m

12.8yrs

Gemiddelde duur

61yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van 4572 is doorgewinterd en ervaren (gemiddelde ambtstermijn van 12.8 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Kohichiro Yoshino	CEO, President & Representative Director	21.6yrs	geen gegevens	1.75% ¥ 103.5m
Emi Yamamoto	GM of Business Mgt.	8.7yrs	geen gegevens	0.29% ¥ 16.9m
Masaaki Sawa	GM of Research & Development Division	9.7yrs	geen gegevens	0.56% ¥ 32.9m
Norio Aikawa	Head of Drug Discovery & Support Business	20.7yrs	geen gegevens	0.53% ¥ 31.6m
Akinori Arimura	GM of Clinical Development	1.7yrs	geen gegevens	0.086% ¥ 5.1m
Tsuguo Ogasawara	Independent Outside Director	4.8yrs	geen gegevens	0.026% ¥ 1.5m
Atsuo Arita	Independent Outside Director	4.8yrs	geen gegevens	0.042% ¥ 2.5m
Teruo Takayanagi	Independent Outside Director	9.7yrs	geen gegevens	0.0058% ¥ 341.0k
Takao Matsui	Independent Outside Director	4.8yrs	geen gegevens	geen gegevens
Kaoru Suzuki	Independent Outside Director	less than a year	geen gegevens	geen gegevens

6.8yrs

Gemiddelde duur

75yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van 4572 wordt beschouwd als ervaren (gemiddelde ambtstermijn 6.8 jaar).

Carna Biosciences Beheer

Beheer criteriumcontroles 2/4

Belangrijke informatie

Recente managementupdates

Carna Biosciences, Inc., Annual General Meeting, Mar 26, 2024

Carna Biosciences, Inc., Annual General Meeting, Mar 24, 2023

Insufficient new directors

Carna Biosciences, Inc., Annual General Meeting, Mar 24, 2022

Carna Biosciences, Inc., Annual General Meeting, Mar 25, 2021

Recent updates

Third quarter 2024 earnings released: JP¥27.37 loss per share (vs JP¥20.13 loss in 3Q 2023)

Carna Biosciences, Inc. to Report Q3, 2024 Results on Nov 08, 2024

Carna Biosciences, Inc. (TSE:4572) Shares May Have Slumped 26% But Getting In Cheap Is Still Unlikely

New major risk - Share price stability

Carna Biosciences, Inc. to Report Q2, 2024 Results on Aug 07, 2024

New minor risk - Shareholder dilution

First quarter 2024 earnings released: JP¥23.21 loss per share (vs JP¥32.77 loss in 1Q 2023)

What Carna Biosciences, Inc.'s (TSE:4572) P/S Is Not Telling You

Carna Biosciences, Inc. to Report Q1, 2024 Results on May 10, 2024

Full year 2023 earnings released: JP¥68.57 loss per share (vs JP¥99.07 loss in FY 2022)

Carna Biosciences, Inc., Annual General Meeting, Mar 26, 2024

Carna Biosciences, Inc. to Report Fiscal Year 2023 Results on Feb 09, 2024

Third quarter 2023 earnings released: JP¥20.13 loss per share (vs JP¥31.91 loss in 3Q 2022)

Carna Biosciences, Inc. to Report Q3, 2023 Results on Nov 07, 2023

New minor risk - Market cap size

Second quarter 2023 earnings released: JP¥21.43 loss per share (vs JP¥25.25 loss in 2Q 2022)

Carna Biosciences, Inc. to Report Q2, 2023 Results on Aug 07, 2023

First quarter 2023 earnings released: JP¥32.77 loss per share (vs JP¥1.12 loss in 1Q 2022)

Full year 2022 earnings released: JP¥99.07 loss per share (vs JP¥42.06 loss in FY 2021)

Full year 2022 earnings released: JP¥99.07 loss per share (vs JP¥42.06 loss in FY 2021)

Carna Biosciences, Inc., Annual General Meeting, Mar 24, 2023

Insufficient new directors

Carna Biosciences, Inc. to Report Q4, 2022 Results on Feb 10, 2023

Carna Biosciences, Inc. announced that it has received ¥11.209315 million in funding from Cantor Fitzgerald & Co.

Carna Biosciences, Inc. announced that it expects to receive ¥11.209315 million in funding from Cantor Fitzgerald & Co.

Third quarter 2022 earnings released: JP¥31.91 loss per share (vs JP¥31.70 loss in 3Q 2021)

Carna Biosciences, Inc. to Report Q3, 2022 Results on Nov 07, 2022

Second quarter 2022 earnings released: JP¥25.25 loss per share (vs JP¥39.45 loss in 2Q 2021)

Carna Biosciences, Inc. to Report Q2, 2022 Results on Aug 05, 2022

First quarter 2022 earnings: EPS exceeds analyst expectations

Carna Biosciences, Inc. to Report Q1, 2022 Results on May 10, 2022

Full year 2021 earnings: EPS misses analyst expectations

Carna Biosciences, Inc., Annual General Meeting, Mar 24, 2022

Consensus revenue estimates increase by 40%

Third quarter 2021 earnings released: JP¥31.70 loss per share (vs JP¥20.32 loss in 3Q 2020)

Consensus forecasts updated

Second quarter 2021 earnings released: JP¥39.45 loss per share (vs JP¥17.31 loss in 2Q 2020)

First quarter 2021 earnings released: JP¥23.06 loss per share (vs JP¥15.22 loss in 1Q 2020)

Health Check: How Prudently Does Carna Biosciences (TYO:4572) Use Debt?

Full year 2020 earnings released: JP¥90.33 loss per share (vs JP¥76.03 profit in FY 2019)

How Much Did Carna Biosciences'(TYO:4572) Shareholders Earn From Share Price Movements Over The Last Five Years?

Full year 2020 earnings released: JP¥90.33 loss per share (vs JP¥76.03 profit in FY 2019)

Revenue beats expectations, earnings disappoint

Carna Biosciences, Inc., Annual General Meeting, Mar 25, 2021

New 90-day high: JP¥1,433

Carna Biosciences, Inc. to Report Fiscal Year 2020 Results on Feb 12, 2021

Health Check: How Prudently Does Carna Biosciences (TYO:4572) Use Debt?

New 90-day low: JP¥1,148

Third quarter 2020 earnings released: JP¥20.32 loss per share

New 90-day low: JP¥1,294

Carna Biosciences, Inc. to Report Q3, 2020 Results on Nov 09, 2020

New 90-day low - JP¥1,371

CEO

Tenure

Leiderschapsteam

Gemiddelde duur

Gemiddelde leeftijd

Bestuursleden

Gemiddelde duur

Gemiddelde leeftijd